Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults

NCT03245619 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
18
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated as relationship between GSK3335065 and ventricular tachycardia could not be excluded.

Conditions

Interventions

Sponsor

GlaxoSmithKline